Zongertinib

Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors[1][2][3].

Product Specifications

CAS Number

[2728667-27-2]

Product Name Alternative

BI 1810631

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Met/HGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zongertinib.html

Purity

99.74

Solubility

DMSO : 30.77 mg/mL (ultrasonic; warming; adjust pH to 7 with 1 M HCL; heat to 60°C)

Smiles

O=C(NC1CCN(CC1)C2=NC=C3N=CN=C(C3=N2)NC4=CC=C(C(C)=C4)OC5=CC(N=CN6C)=C6C=C5)C=C

Molecular Formula

C29H29N9O2

Molecular Weight

535.60

Precautions

H302, H315, H319, H335

References & Citations

[1]WHO Drug Informat ion - World Health Organization (WHO) .|[2]Wilding Birgit, et al. Synthesis of diazino-pyrimidines as anticancer agents: World Intellectual Property Organization, WO2021213800. 2021-10-28.|[3]Li S, et al. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Cancers (Basel) . 2023 May 24;15 (11) :2899.